BBOT BridgeBio Oncology Therapeutics, Inc.: institutional ownership and insider trading
70 funds reported holding $460M of BridgeBio Oncology Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $12.9M, with 16 new positions and 18 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
Famous investors holding BBOT
- Ken Griffin (Citadel Advisors): $19.9M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $804K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $447K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $202K, 0.0% of the portfolio
Largest institutional holders of BBOT
- Cormorant Asset Management, LP — $136M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $37.2M
- Omega Fund Management, LLC — $25.1M
- Alphabet Inc. (GOOG, GOOGL) — $21.5M
- EcoR1 Capital, LLC — $21.5M
- WELLINGTON MANAGEMENT GROUP LLP — $21.3M
- Enavate Sciences GP, LLC — $20.0M
- CITADEL ADVISORS LLC — $19.9M
- Novo Holdings A/S — $17.1M
- BlackRock, Inc. (BLK) — $16.4M
5%+ owners
- Bihua Chen: 22.3% (Schedule 13D/A, filed Jul 6, 2026)